1 drug(s) with this reaction
456 total reports
Bone Density Abnormal has been reported as an adverse reaction across 1 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 456 adverse event reports mention bone density abnormal in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with bone density abnormal, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have bone density abnormal listed in their FDA adverse event reports, sorted by report count:
In addition to bone density abnormal, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
1 drug(s) manufactured by Amgen Inc have bone density abnormal listed in their FDA adverse event reports: ROMOSOZUMAB-AQQG.
There are a combined 456 reports of bone density abnormal across 1 Amgen Inc drug(s) in the FDA adverse event database.